Posted by Michael Wonder on 15 Nov 2016
NICE publishes draft guidance on the use of Cinqaero (reslizumab)
15 November 2016 - NICE has published draft guidance on the use of reslizumab on the NHS.
NICE is minded not to recommend reslizumab within its marketing authorisation, that is, as an add-on to standard therapy for treating severe eosinophilic asthma inadequately controlled despite high- dose inhaled corticosteroids plus another medicinal product for maintenance treatment in adults.
